IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
IPO Year: 2013
Exchange: NYSE
Website: iqvia.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/14/2024 | Buy | Redburn Atlantic | |
9/4/2024 | $275.00 | Outperform | RBC Capital Mkts |
7/24/2024 | $266.00 → $242.00 | Buy → Hold | Jefferies |
6/6/2024 | $270.00 | Buy | Goldman |
2/26/2024 | $290.00 | Outperform | Leerink Partners |
2/15/2024 | Buy → Neutral | Guggenheim | |
2/13/2024 | $285.00 | Buy | BTIG Research |
11/2/2023 | $248.00 → $202.00 | Outperform → Neutral | Robert W. Baird |
9/6/2023 | $260.00 | Buy | HSBC Securities |
3/17/2023 | $265.00 | Buy | Truist |
Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will re
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today introduces IQVIA AI Assistant, a generative AI technology that enables a step-change enhancement in how life science customers receive timely and powerful insights. IQVIA AI Assistant is a user-friendly, conversational text interface that provides immediate and intuitive analytic insights. For the first time, customers can simply ask complex questions about their business and receive comprehensive and reliable answers in moments instead of hours or days. Available insights from IQVIA AI Assistant include brand and t
Award Recognizes Leadership in AI Regulatory and Quality Solutions for Healthcare IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry. Frost & Sullivan's annual Customer Value Leadership Award recognizes the company that offers products or services that customers find superior in overall price, performance and
PHILADELPHIA, Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative. IQVIA One Home for Sites is an industry-wide collaboration designed to simplify site conduct when clinical research staff leverage multiple eClinical technologies from multiple solution providers on a trial. Through single sign-on to a common platform, sites enjoy simplified access to trial technologies from IQVIA and other technology partners that have taken the s
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morgan Stanley Annual Healthcare Conference in New York on Wednesday, September 4, 2024 at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligen
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated for revenue to be between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30 IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro
IQVIA™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix® Assessment 2024 survey, which measures both market impact and delivery effectiveness. The Everest Group report highlights IQVIA's focus on innovation and its comprehensive portfolio of solutions that accelerates drug development from molecule to market. IQVIA partners with customers to plan, generate and disseminate trustworthy clinical and medical evidence which drives the right stakeholder dialogue throughout the asset lifecycle to advance regulatory and healthcare decision making that imp
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will recei
IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the IQVIA SmartSolve Enterprise Quality Management System (eQMS) platform has been selected as the winner of the "Best Use of Artificial Intelligence in Healthcare" award in the 8th Annual MedTech Breakthrough Awards. SmartSolve eQMS is part of IQVIA's suite of purpose-built safety, regulatory and quality technologies, providing a single source of truth for quality compliance. It is the first solution to simplify the complexity of quality compliance and offer a cross-functional, intelligent connection of regulatory a
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
3 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
4 - IQVIA HOLDINGS INC. (0001478242) (Issuer)
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
SC 13G/A - IQVIA HOLDINGS INC. (0001478242) (Subject)
Redburn Atlantic initiated coverage of IQVIA with a rating of Buy
RBC Capital Mkts initiated coverage of IQVIA with a rating of Outperform and set a new price target of $275.00
Jefferies downgraded IQVIA from Buy to Hold and set a new price target of $242.00 from $266.00 previously
Goldman initiated coverage of IQVIA with a rating of Buy and set a new price target of $270.00
Leerink Partners initiated coverage of IQVIA with a rating of Outperform and set a new price target of $290.00
Guggenheim downgraded IQVIA from Buy to Neutral
BTIG Research initiated coverage of IQVIA with a rating of Buy and set a new price target of $285.00
Robert W. Baird downgraded IQVIA from Outperform to Neutral and set a new price target of $202.00 from $248.00 previously
HSBC Securities initiated coverage of IQVIA with a rating of Buy and set a new price target of $260.00
Truist initiated coverage of IQVIA with a rating of Buy and set a new price target of $265.00
Jefferies analyst David Windley downgrades IQVIA Hldgs (NYSE:IQV) from Buy to Hold and lowers the price target from $266 to $242.
During the last three months, 13 analysts shared their evaluations of IQVIA Hldgs (NYSE:IQV), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 6 3 0 0 Last 30D 2 3 1 0 0 1M Ago 0 2 1 0 0 2M Ago 1 0 0 0 0 3M Ago 1 1 1 0 0 Analysts have set 12-month price targets for IQVIA Hldgs, revealing an average target of $265.62, a high estimate of $300.00, and a low estimate of $230.00. This upward trend is evident, with the current average reflecting a
Morgan Stanley analyst Tejas Savant maintains IQVIA Hldgs (NYSE:IQV) with a Overweight and raises the price target from $270 to $280.
UBS analyst Dan Brennan maintains IQVIA Hldgs (NYSE:IQV) with a Buy and raises the price target from $295 to $300.
Truist Securities analyst Jailendra Singh maintains IQVIA Hldgs (NYSE:IQV) with a Buy and raises the price target from $292 to $300.
IQVIA Holdings Inc (NASDAQ:IQV) posted better-than-expected second-quarter earnings on Monday. IQVIA reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57. Provider of advanced analytics reported sales of $3.81 billion, beating the consensus of $3.79 billion, according to data from Benzinga Pro. Technology & Analytics Solutions (TAS) revenue of $1.5 billion increased 2.7% on a reported basis and 3.8% at constant currency. Research & Development Solutions (R&DS) revenue reached $2.15 billion, increasing 2.4% on a reported basis and 3.3% at constant currency. "IQVIA delivered second-quarter results at the high-end of our guidance, driven mainly by bett
Evercore ISI Group analyst Elizabeth Anderson maintains IQVIA Hldgs (NYSE:IQV) with a Outperform and raises the price target from $230 to $270.
Barclays analyst Luke Sergott maintains IQVIA Hldgs (NYSE:IQV) with a Overweight and raises the price target from $255 to $275.
Baird analyst Eric Coldwell maintains IQVIA Hldgs (NYSE:IQV) with a Neutral and raises the price target from $235 to $251.
Wall Street started the new week on a positive note, with all major indices in the green. A rebound in tech stocks following last week’s dips bolstered overall investor sentiment. Investors focused on the start of the tech earnings season, looking past President Joe Biden‘s withdrawal from the reelection campaign. Semiconductor stocks, which plunged last week due to threats of increased curbs on China, rallied on Monday. The VanEck Semiconductor ETF (NYSE:SMH) and the iShares Semiconductor ETF (NYSE:SOXX) both rose by 2.5%. The tech-heavy Nasdaq 100 index surged 1% by 12:40 p.m. in New York, poised to snap a three-day losing streak. The S&P 500 edged up 0.7%, while blue-chip stocks in
10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
10-Q - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
8-K - IQVIA HOLDINGS INC. (0001478242) (Filer)
144 - IQVIA HOLDINGS INC. (0001478242) (Subject)
144 - IQVIA HOLDINGS INC. (0001478242) (Subject)
Revenue of $3,896 million GAAP Net Income of $285 million, Adjusted EBITDA of $939 million GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported year-over-year TAS Revenue of $1,554 million, up 8.6 percent year-over-year Operating Cash Flow of $721 million, bringing year-to-date Operating Cash Flow to $1,831 million, up 31 percent year-over-year Free Cash Flow of $571 million, bringing year-to-date Free Ca
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will re
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted Diluted Earnings per Share of $2.64 R&D Solutions quarterly bookings of $2.7 billion, representing a book-to-bill ratio of 1.27x R&D Solutions contracted backlog of $30.6 billion, up 7.7 percent reported and 8.1 percent at constant currency year-over-year Full-year 2024 guidance updated for revenue to be between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30 IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global pro
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will recei
Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2024. First-Quarter 2024 Operating Results Revenue for the first quarter of $3,737 millio
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2024 financial results before the market opens on Thursday, May 2, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receiv
Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Diluted Earnings per Share of $2.54 for the fourth quarter, $7.29 for the full year Adjusted Diluted Earnings per Share of $2.84 for the fourth quarter, $10.20 for the full year R&D Solutions quarterly bookings of over $2.8 billion, representing book-to-bill ratio of 1.31x R&D Solutions contracted backlog of $29.7 billion grew 9.2 percent year-over-year Full-year 2024 revenue guidance of $15,400 million to
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its fourth-quarter and full-year 2023 financial results before the market opens on Wednesday, February 14, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, pa
Revenue of $3,736 million grew 4.9 percent year-over-year GAAP Net Income of $303 million grew 7.1 percent year-over-year Adjusted EBITDA of $888 million grew 9.1 percent year-over-year GAAP Diluted Earnings per Share of $1.63 grew 9.4 percent year-over-year Adjusted Diluted Earnings per Share of $2.49 grew 0.4 percent year-over-year R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.24x R&D Solutions contracted backlog of $28.8 billion grew 12 percent year-over-year IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has appointed Richard Staub III, currently senior advisor to the Chairman and CEO, as president of its Research & Development Solutions (R&DS) business unit. Richard is a vastly experienced executive with 34 years in the life science sector and has held numerous senior executive roles across multiple contract research organizations. Richard previously served as the president of the R&DS business unit at IQVIA from 2016 to 2022. Under his exceptional leadership the R&DS business unit accelerated its growth, recorded consec
IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced the appointment of Dr. Christina Mack to serve as chief scientific officer for the company's Real World Solutions (RWS) business, effective July 7, 2022. Christina is succeeding Dr. Nancy Dreyer, who is retiring after nearly two decades with IQVIA. In this new role, Dr. Mack will be responsible for guiding the design and execution of innovative real-world studies, using advanced enriched evidence to enable faster decision-making and help advance clinical practices. Christina's career at IQVIA has included several leadership roles, all
IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and contract services to the life sciences industry, today announced the appointment of Costa Panagos, to serve as president of its Research & Development Solutions (R&DS) business unit. He is succeeding Richard Staub III, who is retiring after a successful career spanning more than three decades. Mr. Staub will remain with the company as a senior advisor to the CEO and continue supporting business development and client management activities. Mr. Panagos has more than 25 years of industry experience serving life sciences customers and managing contract research (CRO) organizati
IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today. Ms. Stamps brings more than four decades of strategic, governance and operational management experience. During her extensive career she held senior executive leadership positions in both public and private sector organizations, most recently as a senior investment advisor to the Comptroller of the State of New York for the NYS Common Retirement Fund and as Commissioner on the board of the New York State Insurance Fund, the state's largest provider of worker's compensation insurance. Prior to this, she was a Managing Director at Bank of America and Managing Director and Executive
IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, announced the appointment of Leslie Wims Morris to its board of directors, effective today. With more than 25 years of experience in financial services, Wims Morris is currently Managing Director and Head of Corporate Development for JPMorgan Chase's Consumer & Community Banking business, which serves more than 60 million households in the U.S. In this role, she leads the development and launch of strategic partnerships with leading technology, payments, e-commerce and fintech companies and participates in firmwide strategic initiatives. She is also
MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagement of patients for trials related to the clinical development of ASLAN004 and ASLAN003. IQVIA Biotech will provide pati
BOSTON, Sept. 29, 2021 /PRNewswire-PRWeb/ -- Drumroll Health, a digital health company applying AI to simplify how organizations discover new insights from survey data, announced today the appointment of Pablo Graiver as new Chief Executive Officer of the company. Mr Graiver, visionary founder and former CEO of pioneering trial-matching company Antidote, brings an unparalleled wealth of experience and successful track record designing and scaling innovative technology solutions used every day by patients, researchers, and biopharma companies alike. "Drumroll Health is tapping into a very real and pressing need, making it easier and faster to translate survey data into clear, meaningful insig